Kirit Ardeshna

Kirit Ardeshna is a UK haematologist renowned for leading the BNLI/Gemcitabine trial demonstrating benefits of early rituximab versus watchful waiting in asymptomatic low-tumor-burden follicular lymphoma. His research has refined the evidence base for watchful waiting in appropriately selected FL patients and defined criteria for initiating therapy. He contributes to national UK lymphoma guidelines and teaches extensively about individualized management of indolent lymphoma. His work has directly influenced international clinical practice guidelines for FL management.